Idexx Laboratories (IDXX) Beats Q3 Earnings and Revenue Estimates

Impact · against what's priced in

Idexx Laboratories delivered a beat on both the top and bottom lines for Q3 2026, with EPS growing 17.3% year-over-year. Given the stock's 18.5% decline since the start of the year, these results provide a positive fundamental offset to recent price weakness.

IDXX+0.40

No priced-in read yet

In context

The company exceeded expectations with EPS of $3.98 against a $3.71 estimate and revenue of $1.21 billion, surpassing consensus by 2.21%.

Read from the article alone

• earnings▲3%
• healthcare
• fundamental analysis
• IDXX
• animal health
• earnings surprise
• medical instruments

Top 1 mover · tap to explore